Monoclonal antibody combinations in CLL: evolving strategies

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Monoclonal antibodies have transformed chronic lymphocytic leukemia (CLL) therapy.
• Alemtuzumab and rituximab are key agents with established efficacy in various CLL patient groups.
• Combinations of monoclonal antibodies show promise for higher response rates and eradicating minimal residual disease (MRD).

Purpose of the Study:

• To review the impact of monoclonal antibodies in chronic lymphocytic leukemia (CLL) treatment.
• To discuss the evolution of CLL therapy towards curative intent.
• To identify future challenges in monoclonal antibody combination therapies for CLL.

Main Methods:

• Review of current literature on monoclonal antibody therapy in CLL.
• Analysis of single-agent and combination antibody efficacy.
• Discussion of emerging treatment strategies and future research directions.

Main Results:

• Monoclonal antibodies, particularly alemtuzumab and rituximab, are highly active in CLL.
• Combination therapies demonstrate improved response rates and better MRD eradication compared to single agents.
• Therapeutic focus is shifting from palliation to curative approaches in CLL.

Conclusions:

• Monoclonal antibody combinations represent a significant advancement in CLL treatment.
• Future research should address patient stratification, prognostic factors, MRD eradication, and response assessment.
• Optimizing these combinations is crucial for achieving curative outcomes in CLL.